← Back to Search

Other

HH2710 for Tumors

Phase 1 & 2

Waitlist Available

Research Sponsored by Haihe Biopharma Co., Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up about 2 years

Awards & highlights

Study Summary

This trial is testing a new drug (HH2710) to see if it is safe and effective in treating patients with advanced tumors.

Eligible Conditions

Advanced Tumors
Melanoma
Erdheim-Chester Disease
Non-Small Cell Lung Cancer
RAS/RAF/MEK/ERK Mutated Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ about 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~about 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and about 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

DLT (Dose limiting toxicities)

MTD (Maximum Tolerated Dose)

Heart rate

Secondary outcome measures

Pharmacokinetic measures - Apparent clearance (CL/F)

Pharmacokinetic measures - Apparent volume of distribution (Vz/F)

Pharmacokinetic measures - Peak plasma concentration (Cmax)

+4 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Dose escalaltion study of HH2710Experimental Treatment1 Intervention

to determin the MTD of HH2710 and/or Recommended Phase II dose (RP2D).

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Haihe Biopharma Co., Ltd.Lead Sponsor

16 Previous Clinical Trials

1,759 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the ultimate objective of this experiment?

"The focus of this trial is the Tumor Objective Response Rate (ORR), with measurements taken over a two year period. Subsidiary objectives include assessing Plasma elimination half-life (t1/2), Apparent volume of distribution (Vz/F) and Plasma clearance rate constant (λz)."

Answered by AI

Is this medical experiment currently searching for participants?

"Absolutely. Clinicaltrials.gov suggests that this study, which was initially publicized on the 7th of January 2020, is presently enrolling volunteers. In order to complete their research objectives, they need 150 participants from 2 distinct clinical sites."

Answered by AI

What is the enrollment cap for this scientific experiment?

"Affirmative. Clinicaltrials.gov exhibits that this medical trial is currently calling for volunteers, with the initial post dating back to July 1st 2020 and most recent update on September 19th 2022. The research necessitates 150 participants from two separate sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

2020. "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04198818.